Filters

Pp-157 manufacturers

Filters

1 products found

pp-157

Concentrate for solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Recurrent/metastatic HNSCC (1L in combination with pembrolizumab; 2L monotherapy or combinations) Clinical stage: Phase 3 — LiGeR-HN-01 (1L), LiGeR-HN-02 (2L) trials ongoing Modality: Biologic (full-length IgG1 bispecific mAb — Biclonics platform) Mechanism / Target: Simultaneously targets EGFR (overexpressed in HNSCC) and LGR5 (Wnt pathway/cancer stem cell marker) — induces internalisation and degradation of EGFR, blocking tumour cell proliferation and stem cell renewal Route / form: Intravenous infusion Differentiation: Dual target engagement provides deeper/more durable EGFR inhibition vs cetuximab; LGR5 co-targeting may reduce resistance; Phase 2 data showed 37% ORR and 16-month OS in 2L HNSCC
Manufacturer #15110

Clinical-stage oncology company developing bispecific antibodies using a proprietary Biclonics platform. Advances differentiated multi-target engaging biologics for gastrointestinal and other solid cancers. Wholly owned pipeline with Phase 3 bispecific mAb in head and neck cancer.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.